Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Medigene ( (DE:MDG1) ) is now available.
Medigene AG, a company listed on the Frankfurt Stock Exchange, has announced the departure of its CEO, Dr. Selwyn Ho, whose contract expires on July 24, 2025. Ralph Schäfer, currently the General Counsel, will assume the role of CEO starting July 25, 2025. This leadership change occurs amidst ongoing preliminary insolvency proceedings, although the departures are stated to be unrelated to these proceedings. Additionally, the company has seen recent departures from other key positions, including its Chief Scientific Officer and a member of its Supervisory Board.
The most recent analyst rating on (DE:MDG1) stock is a Buy with a EUR2.00 price target. To see the full list of analyst forecasts on Medigene stock, see the DE:MDG1 Stock Forecast page.
More about Medigene
Average Trading Volume: 25,442
Technical Sentiment Signal: Sell
Current Market Cap: €1.91M
For detailed information about MDG1 stock, go to TipRanks’ Stock Analysis page.